Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;48(1):24-35.
doi: 10.4070/kcj.2017.0194.

Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution

Davide Capodanno  1
Affiliations
Review

Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution

Davide Capodanno. Korean Circ J. 2018 Jan.

Abstract

Bioresorbable scaffolds (BRS) represent a novel paradigm in the 40-year history of interventional cardiology. Restoration of cyclic pulsatility and physiologic vasomotion, adaptive vascular remodeling, plaque regression, and removal of the trigger for late adverse events are expected BRS benefits over current metallic drug-eluting stents. However, first-generation BRS devices have significant manufacturing limitations and rely on optimal implantation technique to avoid experiencing an excess of clinical events. There are currently at least 22 BRS devices in different stages of development, including many trials of device iterations with thinner (<150 μm) struts than first-generation BRS. This article reviews the outcomes of commercially available and potentially upcoming BRS, focusing on the most recent stages of clinical development and future directions for each scaffold type.

Keywords: ABSORB; Angioplasty; Biodegradable stents; Bioresorbable scaffolds; Coronary stents.

PubMed Disclaimer

Conflict of interest statement

Speaker and consulting fees from Abbott Vascular, Santa Clara, CA, USA.

Figures

Figure 1
Figure 1
Strut thickness of early and current generation BRS. BRS = bioresorbable scaffolds.
Figure 2
Figure 2
Key features of BRS currently approved by the CE. BRS = bioresorbable scaffolds; CE = European Conformity; Mg = magnesium; PDLLA = poly-d,l-lactic acid; PLLA = poly-l-lactic acid; TP = tyrosine polycarbonate.
Figure 3
Figure 3
Schematic representation of the parabolic trajectory of the first-generation ABSORB BRS. After presentation of 3-year follow-up results of the ABSORB 2 trial, the gap between expectations and reality appears unacceptable. This has been corroborated by 2-year follow-up results of the ABSORB 3 trial, the AIDA trial, and subsequent meta-analyses. Technological refinements and adherence to strict implantation protocol are necessary to bring this technology to the next phase. AIDA = Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial; BRS = bioresorbable scaffolds.
See this image and copyright information in PMC

References

    1. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol. 2013;62:1915–1921. - PubMed
    1. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168–182. - PubMed
    1. Capodanno D, Angiolillo DJ. Antiplatelet therapy after implantation of bioresorbable vascular scaffolds: a review of the published data, practical recommendations, and future directions. JACC Cardiovasc Interv. 2017;10:425–437. - PubMed
    1. Capodanno D. Bioresorbable scaffolds: clinical outcomes and considerations. Interv Cardiol Clin. 2016;5:357–363. - PubMed
    1. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–1153. - PubMed

LinkOut - more resources